Taking roughly 0.1 to 0.3 grams of dried psilocybin mushrooms on a repeating schedule, typically every third day, defines the practice of microdosing for depression.1 to 0.3 grams of dried psilocybin every few days, an amount so small that no psychedelic trip occurs. Larger clinical doses have shown real promise for treatment-resistant depression, and many adults report that scheduled sub-perceptual amounts lift mood, soften rumination, and sharpen focus.
The evidence for the microdose range itself remains thin, which shapes every claim that follows.
This guide covers what a true microdose is, what the research actually shows, and how to follow a structured protocol safely so you can make a careful decision for your situation.
What Microdosing Psilocybin Actually Means
A microdose is a sub-perceptual amount of dried psilocybin mushrooms, generally 0.1 to 0.3 grams for most adults. Sub-perceptual means you should not feel high, see visuals, or lose your grip on ordinary reality. Many people describe the effect as a quiet lift, a softened mood, or a more reflective day, the kind of change a friend might not notice from the outside.
Microdose vs. Threshold Dose
A true microdose stays below the perceptual threshold, where sensory shifts, color brightening, or emotional waves start to appear. Once you cross 0.4 grams, you enter threshold territory, and at 0.5 grams many people begin to feel something closer to a low-dose experience. Staying in the sub-perceptual range is what separates microdosing from ceremonial use, and it is the line between a quiet mood lift and a day that takes over your schedule.
How Microdosing Differs from Clinical Psilocybin Therapy
Supervised clinical trials typically administer 10 mg or 25 mg of synthetic psilocybin inside a guided session with two therapists, preparation beforehand, and integration afterward. Microdosing skips that frame and uses natural dried mushrooms in much smaller amounts, which means the experience is woven into normal life rather than held inside a clinical day. You trade the safety net of a guided session for the convenience of dosing at home, and that tradeoff should shape your decision.
With that context set, the harder question is whether the antidepressant claims hold up under scrutiny.
Psilocybin received FDA Breakthrough Therapy designation in 2018 and 2019 for treatment-resistant depression. That designation reflects full-dose trial results, not microdosing outcomes.
The Evidence Base for Microdosing and Depression
Large-scale, placebo-controlled microdosing trials for depression do not exist yet, and that gap shapes every claim you see. Most of what circulates online comes from self-reports, small open-label studies, and surveys of people who already chose to microdose, samples that skew toward early adopters and people who felt well enough to respond.
What Full-Dose Trials Have Shown
Striking results have emerged from full-dose psilocybin studies in treatment-resistant depression and major depressive disorder, with some participants showing large, lasting improvements after one or two supervised sessions. Those results are real, and they explain the excitement. They do not, however, automatically translate to taking 0.15 grams on a Tuesday morning with no therapist present, and you should weigh the two setups separately rather than assume the effects will scale down cleanly.
Proposed Mechanisms
Researchers point to two main ideas. First, psilocybin activates serotonin 2A receptors, which appears to disrupt rigid patterns of negative thinking, the kind of looping rumination that defines clinical depression. Second, animal and early human studies suggest psilocybin increases neuroplasticity, the brain’s ability to form new connections, which may help you break out of entrenched mood states. Together, those mechanisms offer a plausible story for why a sub-perceptual amount might still nudge mood without producing a trip.
Who the Research Excludes
Most trials exclude people taking SSRIs or SNRIs, people with bipolar disorder, anyone with a personal or family history of psychosis, and pregnant or nursing participants. If you fall into any of those groups, the existing evidence base does not describe what happens to you, and the cautious move is to assume the risks are higher, not lower, than for trial participants. Apply that same caution to your own plan before you commit to a protocol.
Comparing the Fadiman, Stamets, and Intuitive Protocols
Three dosing schedules dominate the conversation, and each one rests on a different theory about how psilocybin affects mood over time.
| Protocol | Schedule | Best Fit |
|---|---|---|
| Fadiman Protocol | One dose every 3 days for 2 to 4 weeks | Structured beginners who want a clear routine |
| Stamets Stack | 4 days on, 3 days off, often with lion’s mane and niacin | Experienced users comfortable with supplements |
| Intuitive Protocol | Dose only when symptoms feel present | Symptom-led users who want flexibility |
The Fadiman Protocol
Psychologist James Fadiman proposed taking a microdose on day one, skipping days two and three, and dosing again on day four. The cycle repeats for at least two weeks. The every-third-day spacing is designed to prevent tolerance buildup and to let you observe each dose day against two clear baseline days, which makes it easier to tell whether the protocol is doing anything for your mood.
The Stamets Stack
Mycologist Paul Stamets popularized a four-days-on, three-days-off pattern, often combined with lion’s mane mushroom extract and niacin (vitamin B3). The idea is that lion’s mane may support neuroplasticity and that the niacin flush may help distribute psilocybin to nerve endings, though those proposed mechanisms are not yet clinically validated. If you choose this protocol, treat the supplements as a hypothesis to test, not an established synergy.
The Intuitive Protocol
The intuitive approach drops the calendar entirely. You dose on a hard day, when depressive symptoms feel loud, and you skip on a good day. Some people find this approach the most humane, while others find that without structure they end up dosing too often and quietly losing the benefit. Be honest with yourself about which pattern matches your decision-making style.
Once you have committed to a structure, the practical work of measuring each dose with real precision begins.
Measuring, Preparing, and Storing a Reliable Microdose
Because dried psilocybin mushrooms vary in potency by strain, growing conditions, and even flush, accurate measurement is the single most important safety skill in microdosing. Without it, a “small” amount can quietly drift into perceptual territory.
Sourcing and Potency Variance
Buy from a trusted supplier who can tell you the strain and ideally the approximate psilocybin percentage. Two batches of the same species can differ by a factor of two or more, so treat every new batch as a fresh unknown until you have tested it at the low end of your range. That caution protects you from an accidental threshold experience on a day when you have work or family responsibilities.
Weighing on a Milligram Scale
A non-negotiable tool for accurate dosing is a milligram scale, the kind sold for kitchen or jewelry use, capable of measuring to the hundredth of a gram. A kitchen teaspoon is not accurate enough. As a worked example, 0.15 grams equals 150 mg, which sits squarely inside the typical microdose range for many adults and gives you a clean starting point for your own titration.
Tip: Build a quick dosing error check before each session. Weigh your dose, then ask yourself whether the number matches your target. Catching a doubling mistake before ingestion can prevent an accidental perceptual experience.
Capsule Preparation
Size 0 or 00 gelatin or vegan capsules hold roughly 0.15 to 0.3 grams of finely ground dried mushroom when loosely packed. Pre-filling a two-week supply gives you consistent, repeatable doses and makes your routine easier to maintain, especially when traveling, since a labeled pill bottle is far less conspicuous than loose mushroom powder.
Storage for Potency
Store dried mushrooms in an airtight container with a food-safe desiccant packet, kept in a cool, dark place. Psilocybin degrades over time when exposed to heat, light, and moisture, so a sealed jar in a cupboard outperforms a baggie on a shelf. Treat your supply the way you would treat any light-sensitive medication.
Tracking Results and Knowing When to Pause or Stop
A daily tracker turns microdosing from a vague feeling into data you can act on. Without one, you will struggle to tell whether the protocol is helping, doing nothing, or quietly making things worse.
Daily Tracker Template
Track each of these on a 1 to 10 scale every day of your protocol:
- Mood, overall emotional state, with a short note about the worst moment of the day.
- Sleep, hours slept, how rested you felt, and any vivid dreams.
- Anxiety, physical tension, worry, or panic symptoms, scored separately from mood.
- Energy, motivation and physical drive, distinct from mood.
- Social engagement, how connected you felt to other people.
- Side effects, nausea, headaches, jitteriness, or anything new that showed up.
When to Pause or Stop
Stop and seek qualified help if you notice new or worsening suicidal thoughts, panic attacks, manic episodes (racing thoughts, reduced sleep need, impulsive decisions), or persistent insomnia that lasts beyond a single dose day. These are clinical red flags, not experiments to push through, and your safety matters more than any protocol’s continuity.
Reassessment Windows
Review your tracker at two weeks, four weeks, and eight weeks. After eight weeks, a clear pattern should be visible. If your scores are improving, you may continue with a clinician’s input. If they are flat or worsening, the honest conclusion is that microdosing is not the right tool for you right now, and that conclusion is useful information rather than a personal failure.
Drug Interactions, Mental Health Risks, and the Legal Landscape
Microdosing does not exist in a vacuum. It lands on top of any psychiatric medications you are already taking, any vulnerabilities in your mental health history, and a legal picture that varies sharply by where you live.
Drug Interactions
The interaction between psilocybin and SSRIs or SNRIs is not fully understood, though many users report a blunted effect when combining the two. Combining psilocybin with lithium, a common bipolar medication, has been linked in case reports to seizures. MAOIs and antipsychotics carry their own combination risks that a qualified clinician needs to evaluate before you start, adjust, or combine any of these, so bring your full medication list to your next appointment rather than experimenting on your own.
Mental Health Risk Flags
Microdosing carries elevated risk for people with bipolar disorder, psychotic disorders such as schizophrenia, or a first-degree relative with psychosis. Even sub-perceptual amounts can occasionally destabilize mood or trigger symptoms in people with those vulnerabilities, which is why honest screening matters before any dose. Take your own family history seriously before you commit to a protocol.
Legal Status in the United States
| Level | Status | Practical Effect |
|---|---|---|
| Federal | Schedule I controlled substance | Possession is a federal offense nationwide |
| State | Varies by state | A few states have begun reform pathways |
| City | Decriminalized in Denver, Oakland, Seattle, and others | Lowest local enforcement priority, not legal |
Federal Schedule I status applies everywhere in the US. State and city reforms change enforcement priorities, not the underlying prohibition, which means the legal risk remains real regardless of where you live. Factor that risk into your decision before you source or carry any amount.
Bringing a Clinician Into the Plan
The single most useful thing you can do before starting is talk with a qualified mental health professional about your specific situation, your medications, and your goals. A clinician who is familiar with psychedelics can help you interpret your tracker data, catch warning signs early, and decide whether microdosing fits into your broader treatment plan. That conversation protects you in ways no protocol alone can.
Bring all of this to a clinician who can interpret the data alongside your full history.
Bottom Line
Microdosing psilocybin for depression is a sub-perceptual practice, generally 0.1 to 0.3 grams every few days, that sits alongside, not instead of, full-dose clinical research. The protocols (Fadiman, Stamets, intuitive) differ mainly in structure, while accurate measurement, consistent tracking, and clinician oversight are what keep the practice safe. If you have a complex medication list, a bipolar or psychosis history, or any sign of destabilizing symptoms, pause and bring them to a qualified professional before continuing.
FAQ
What is the best psilocybin microdose for depression?
Most protocols place a true microdose between 0.1 and 0.3 grams of dried mushrooms, with 0.15 grams as a common starting point. Dose-response varies by body weight, metabolism, mushroom potency, and current medications, so starting low and adjusting slowly with a clinician’s input is the safest approach for your situation.
How often should you microdose mushrooms for depression?
The most evidence-informed schedules dose every third day (Fadiman) or four days on and three days off (Stamets). Daily dosing is discouraged because psilocybin tolerance builds quickly, and consecutive-day use may blunt the effect and increase side effects without added benefit, so spacing your doses protects your results over time.
Are there risks of microdosing psilocybin for depression?
Known risks include anxiety, nausea, sleep disruption, and worsening mood in some users, plus higher concern for people with bipolar disorder, psychosis risk, or those taking SSRIs, lithium, MAOIs, or antipsychotics. Anyone with a complex medication list or psychiatric history should review the plan with a qualified clinician before starting.
How long does it take for psilocybin microdosing to help depression?
Most self-report timelines suggest two to four weeks of consistent dosing before any meaningful shift, with reassessment points at two, four, and eight weeks. If no improvement is visible by eight weeks, microdosing is unlikely to be the right tool for your situation, and you can move on to other options with that information in hand.
What is the difference between microdosing psilocybin and taking antidepressants?
Antidepressants such as SSRIs are taken daily, work through continuous serotonin reuptake inhibition, and are prescribed and monitored by a clinician. Microdosing psilocybin is taken on a spaced schedule, may work through serotonin 2A receptor activation and increased neuroplasticity, and is currently unregulated, so tracking and clinician input become the substitute for prescription oversight in your routine.
Can you build a tolerance when microdosing mushrooms daily?
Yes, and quickly. Psilocybin tolerance builds within one to three consecutive days of use and fades after about a week off, which is why every established protocol schedules dose-free days rather than daily use. Daily microdosing is the most common self-inflicted mistake in the practice, and avoiding it keeps your protocol effective.
